1,2-bis[(E)-[4-(dimethylamino)phenyl]methylideneamino]guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,2-bis[(E)-[4-(dimethylamino)phenyl]methylideneamino]guanidine
• 化学式: C₁₉H₂₅N₇
• 分子量: 351.4
• InChiKey: DBTHUYFRHDODRL-JFMUQQRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  81.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• COMPOUNDS AND METHODS OF TREATING INFECTIONS
  申请人：GARG Sanjay

  公开号：US20160075665A1

  公开（公告）日：2016-03-17

  The invention provides compounds of Formula (I), and methods of treating or preventing a bacterial infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a bacterial infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a bacterial infection in a subject and to a medical device comprising the composition of the invention.

  本发明提供了化合物(I)的方法，以及使用化合物(I)治疗或预防受体内细菌感染的方法。本发明还提供了使用化合物(I)制造治疗受体内细菌感染的药物的方法。本发明还提供了在治疗或预防受体内细菌感染的方法中使用的医疗设备，以及包含本发明化合物的医疗设备。
• ROBENIDINE ANALOGS AS POTENT ANTIMALARIALS AGAINST DRUG-RESISTANT PLASMODIUM FALCIPARUM
  申请人：OREGON HEALTH & SCIENCE UNIVERSITY

  公开号：US20220267258A1

  公开（公告）日：2022-08-25

  Provided herein is a compound of Formula (I): wherein: R 1 is selected from the group of —F, —Cl, —Br, —I, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, —NO 2 , —C(H)═O, ═O, —CN, and COOR 3 ; R 2 is selected from the group of H and C 1 -C 3 alkyl; and R 3 is selected from the group of H, C 1 -C 6 alkyl, and benzyl; or a pharmaceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer (including optical isomers, racemates, or other mixtures thereof), tautomer, isotope, polymorph, or pharmaceutically acceptable prodrug thereof, along with pharmaceutical compositions and methods of using the compound in the treatment of malaria, particularly including drug-resistant malaria.

  提供的是化合物I的公式：其中：R1选自—F，—Cl，—Br，—I，C1-C6卤代烷基，C1-C6卤代氧烷基，—NO2，—C（H）═O，═O，—CN和COOR3的组；R2选自H和C1-C3烷基；R3选自H，C1-C6烷基和苄基；或其药学上可接受的盐，共晶体，酯，溶剂合物，水合物，异构体（包括光学异构体，外消旋体或其他混合物），互变异构体，同位素，多晶形或其药学上可接受的前药，以及使用该化合物治疗疟疾的药物组合物和方法，特别是包括耐药性疟疾。
• Compounds and methods of treating infections
  申请人：Neoculi Pty Ltd.

  公开号：US10253002B2

  公开（公告）日：2019-04-09

  The invention provides compounds of Formula I, and methods of treating or preventing a bacterial infection in a subject using a compound of Formula I. The invention also provides the use of a compound of Formula I in the manufacture of a medicament for the treatment of a bacterial infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a bacterial infection in a subject and to a medical device comprising the composition of the invention.

  本发明提供了式 I 化合物，以及使用式 I 化合物治疗或预防受试者细菌感染的方法。本发明还提供了式 I 化合物在制造治疗受试者细菌感染的药物中的用途。本发明进一步提供了一种用于治疗或预防受试者细菌感染方法中的医疗器械，以及包含本发明组合物的医疗器械。
• Methods for treating protozoan infections
  申请人：Neoculi Pty Ltd.

  公开号：US10392363B2

  公开（公告）日：2019-08-27

  The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.

  本发明提供了式(I)化合物及其在使用式(I)化合物治疗或预防受试者原生动物感染的方法中的用途。本发明还提供了式 (I) 化合物在制造治疗受试者原生动物感染的药物中的用途。本发明进一步提供了一种用于治疗或预防受试者原生动物感染方法中的医疗器械，以及包含本发明组合物的医疗器械。
• METHODS FOR TREATING PROTOZOAN INFECTIONS
  申请人：Neoculi Pty Ltd.

  公开号：US20170291886A1

  公开（公告）日：2017-10-12

  The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.